JP Patent

JP7126514B2 — アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス

Assigned to Yuhan Corp · Expires 2022-08-26 · 4y expired

What this patent protects

Patent listed against lazertinib-mesylate.

Drugs covered by this patent

lazertinib-mesylate (LAZERTINIB MESYLATE)

Patent Metadata

Patent number: JP7126514B2
Jurisdiction: JP
Classification: —
Expires: 2022-08-26
Drug substance claim: No
Drug product claim: No
Assignee: Yuhan Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.